PANEL IV: BUILDING ENVIRONMENT AND USING EM/LIGHT – OVERVIEW & BEST PRACTICES AND USE OF EM/LIGHT TO DATE, GAPS IN RESEARCH

David Jay Weber, M.D., M.P.H., FSHEA, FIDSA, FRSM (London) Professor of Medicine, Pediatrics, Epidemiology Associate Chief Medical Officer, UNC Hospitals Medical Director, Hospital Epidemiology University of North Carolina at Chapel Hill

Disclosures: Consultant to Germitec, PDI, Lumagenics, Merck, Pfizer

EVIDENCE THAT ENVIRONMENTAL CONTAMINATION LEADS TO PATIENT ACQUISITION OF MDROS AND THAT IMPROVED TERMINAL CLEANING/DISINFECTION REDUCES HAIS

- Surfaces are contaminated-~25-50% multidrug-resistant organisms (MDROs)
- MDROs survive days to months
- Rooms not adequately cleaned (i.e., <50% cleaned)
- Rooms are frequently contaminated post-terminal disinfection
- Disinfection reduces contamination
- Contact with surfaces results in hand/glove contamination
- Improved terminal disinfection reduces HAIs
- Enhanced terminal disinfection (e.g., UV-C devices) reduces risk of MDR colonization/infection in subsequent patient admitted to the room
- Enhanced terminal disinfection of rooms with a colonized or infected patient may lead to hospital-wide decrease in HAIs



Weber D, Kanamori H, Rutala W. Curr Op Infect Dis 2016:29:424-431

EVIDENCE THAT ALL TOUCHABLE ROOM SURFACES ARE EQUALLY CONTAMINATED

Precleaning and Postcleaning Bacterial Load Mea-TABLE 1. surements for High-, Medium-, and Low-Touch Surfaces

	Mean CFUs/RODAC (95% CI)				
Surface (no. of samples)	Precleaning	Postcleaning			
High $(n = 40)$	71.9 (46.5–97.3)	9.6 (3.8–15.4)			
Medium $(n = 42)$	44.2 (28.1–60.2)	9.3 (1.2–17.5)			
Low $(n = 37)$	56.7 (34.2–79.2)	5.7 (2.01–9.4)			

Huslage K, Rutala W, Gergen M, Sickbert-Bennett S, Weber D ICHE 2013;34:211-2

CFU, colony-forming unit; CI, confidence interval. NOTE.

Ward		Culture sites ^a							
	HCWs' hands	Surfaces distant from patients	Surfaces close to patients	Prevalence of contamination					
Α	3/10 (30%)	0/22 (0%)	6/25 (24.0%)	9/57 (15.8%)					
В	2/9 (22.2%)	4/19 (21.1%)	5/48 (10.4%)	11/76 (14.5%)					
С	2/10 (20%)	2/26 (7.7%)	7/49 (14.3%)	11/85 (12.9%)					
D	1/9 (11.1%)	2/24 (18.2%)	7/45 (15.6%)	10/78 (12.8%)					
E	0/5 (0%)	4/22 (18.2%)	3/30 (10%)	7/57 (12.3%)					
F	1/10 (10%)	0/11 (0%)	4/31 (12.9%)	5/52 (9.6%)					
G	0/3 (0%)	2/14 (14.3%)	0/20 (0%)	2/37 (5.4%)					
Н	1/10 (10%)	0/16 (0%)	1/55 (1.8%)	2/81 (2.5%)					
Total	10/66 (15.2%)	14/154 (9.1%)	33/303 (10.9%)	57/523 (10.9%)					

Willi I, Mayre A, Kreidl P, et al. JHI 2018;98:90-95

^a Number of contaminated samples/number of samples obtained.

INCREASING BIOBURDEN ASSOCIATED WITH INCREASED HAIs: DECREASED BIOBURDEN ASSOCIATED WITH DECREASED HAIs

Table 1. Epidemiologically-important pathogens (EIP) by intervention and contamination in 92 patient rooms during the benefits of enhanced terminal room disinfection study.

	· · · · · · · · · · · · · · · · · · ·	Mean (CFU/125 cm	² (5 Rodac		P-value		
			by treat	ment type				
Room type	Pathogen	Quat (N=21	Quat/UV (N=28	Bleach (N=23	Bleach/UV (N=20	Quat vs Quat/UV	Quat vs Bleach	Quat vs Bleach/UV
		rooms)	rooms)	rooms)	rooms)			·
Patient room only	MDR-Acinetobacter	8.76	0.18	0.39	0.25			
	C. difficile	0	0.07	0.04	0			
	MRSA	2.33	0.11	2.13	0.05			
	VRE	8.62	0.07	0.78	0.35			
	EIP ^a	19.71	0.43	3.35	0.65	0.013		
Bathroom only	MDR-Acinetobacter	0.19	0	0	0	0.018	0.032	0.045
	C. difficile	3.76	2.79	4.43	3.25			
	MRSA	6.19	0	2.26	0.80	0.044		
	VRE	30.95	0.14	1.65	1.55			
	EIP ^a	41.10	2.93	8.35	5.60	0.015		
Patient/Bathroom ^b	MDR-Acinetobacter	8.95	0.18	0.39	0.25	0.017	0.035	
	C. difficile	3.76	2.86	4.48	3.25			
	MRSA	8.52	0.11	4.39	0.85	0.032		
	VRE	39.57	0.21	2.43	1.90	0.034		
	EIP ^a	60.81	3.36	11.70	6.25	0.001		

Table 2. Relationship between microbial reduction of epidemiologically-important pathogens (EIP) and colonization/infection in a patient subsequently admitted to a room of a patient colonized/infected with an EIP by decontamination method.

Standard Method		Enhanced method		
Quat	Quat/UV	Bleach	Bleach/UV	
60.8	3.4	11.7	6.3	
	94	81	90	
2.3	1.5	1.9	2.2	
	35	17	4	
	Quat 60.8	Quat Quat/UV 60.8 3.4 94 2.3	Quat Quat/UV Bleach 60.8 3.4 11.7 94 81 2.3 1.5 1.9	




FIGURE 2. Quartile distribution of healthcare-acquired infections (HAIs) stratified by microbial burden measured in the intensive care unit (ICU) room during the patient's stay. There was a significant association between burden and HAI risk (P = .038), with 89% of HAIs occurring among patients cared for in a room with a burden of more than 500 colony-forming units (CFUs)/100 cm².

Rutala WA,Weber DJ. ICHE 2018;39:1118-1121

Salgado CD, et al. ICHE 2013;34:479-86

FACTORS AFFECTING UV ROOM DISINFECTION DEVICE EFFECTIVENESS

- Intensity of UV delivered (i.e., energy)
- Wavelength of UV
- Distance (energy delivered falls off as a square of distance)
- Duration of exposure
- Orientation of the surface being disinfected to the UV light (UV energy delivered is line of sight)
 - For shadowed surfaces, UV reflectivity of walls
- Intrinsic susceptibility of microbes (e.g., spore formers such as *C. difficile* more difficult to inactivate than vegetative bacteria such as MRSA and VRE
- Study variables: 1) spreading the inoculum over a greater surface area enhances killing; 2) organic load (e.g., 10% fetal calf serum) significantly decreases killing; 3) test surface does not affect killing (e.g., Formica, glass, steel)
- UV device options: 1) Room disinfection units; 2) Portable handheld units; 3) Shielding around patient beds allowing use of a UV device in a multi-bed room

Adapted from, Cadnum JL, et al. ICHE 2016;37:555-560

VALIDATING UV DEVICES FOR ROOM DISINFECTION

• Progression of studies

- Studies demonstrating microbial inactivation on artificially contaminated surfaces (assessing all UV variables)
- Studies demonstrating microbial inactivation on contaminated surfaces in healthcare facilities
- Studies demonstrating reduction in HAIs
- Types of epidemiologic studies: 1) Efficacy; 2) Effectiveness; 3) Efficiency
- Factors that should be measured (ideally) for efficacy/effectiveness studies: 1) Colonization of patients; 2) Infection in patients; 3) Confounders (hand hygiene compliance, cleaning compliance; 4) Cost; 4) Delays in admission to the room; 5) Transmission pathways of microbes (requires molecular techniques)
- Issues in study design: 1) Non-independence of outcomes; 2) Controlling for confounding; 3) HAIs are now low frequency events
- A key question: Are all UV room disinfection devices similar or do we need validation of each device

CLINICAL TRIALS OF "NO TOUCH" METHODS FOR TERMINAL DISINFECTION

Year, author	Device/system	Study design	Setting	Selected results ^a
2016, Vianna <i>et al.</i> [44]	UV-PX	Before-after	Community hospital	Facility wide: ↓ <i>C. difficile</i> , ↓all MDROs (MRSA, VRE, CDI)
2015, Horn and Otter [45]	HP vapor	Before-after	Hospital	↓CDI, ↓VRE, ↓ESBL GNB
2015, Anderson et al. [46]	UV-C	RCT	9 hospitals	↓All MDROs (MRSA, VRE, CDI)
2015, Pegues et al. [47]	UV-C	Before-after	Academic center	↓CDI
2015, Nagaraja <i>et al.</i> [48]	UV-PX	Before-after	Academic center	↓CDI
2015, Miller <i>et al.</i> [49]	UV-PX	Before-after	Nursing home	↓CDI
2014, Mitchell et al. [50]	Dry HP vapor	Before-after	Hospital	↓MRSA colonization and infection
2014, Haas et al. [51]	UV-PX	Before-after	Academic center	↓CDI, ↓MRSA, ↓VRE, ↓MDRO GNB, all MDROs
2013, Manian <i>et al.</i> [52]	HP vapor	Before-after	Community hospital	↓CDI
2013, Passaretti <i>et al.</i> [53]	HP vapor	Prospective cohort	Academic center	↓VRE, ↓all MDROs (MRSA, VRE, CDI)
2013, Levin <i>et al.</i> [54]	UV-PX	Before-after	Community hospital	↓CDI, ↓MRSA,
2011, Cooper et al. [55]	HP vapor	Before–after (2 cycles)	Hospitals	↓CDI (cases; incidence not significant)
2008, Boyce et al. [56]	HP vapor	Before-after	Community hospital	↓CDI

CDI, *Clostridium difficile* infection; ESBL, extended spectrum beta-lactamase producers; GNB, Gram negative bacteria; HP, hydrogen peroxide; MDRO, multidrugresistant organism; MRSA, methicillin-resistant *Staphylococcus aureus*; UV-C, ultraviolet light – C; UV-PX, ultraviolet light – pulsed xenon; VRE, vancomycinresistant *Enterococcus*.

^aAll listed results were statistically significant (see reference for more details).

Weber DJ,et al. Curr Opin Infect 2016;29:424-431

EFFICACY OF UV AT TERMINAL DISINFECTION TO REDUCE HAIs (A = C. difficile, B = VRE)

А				Risk Rati	0			Risk Ratio		
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random,				IV, Random, 959	% CI	
Anderson 2017	0	0.25	29.0%	1.00 [0.61	. 1.63]			-+-		
Bernard 2015	-0.53		12.6%	0.59 [0.28						
Haas 2014	-0.19	1.67	0.7%	0.83 [0.03,	-					
Levin 2013	-0.76	0.57	5.6%	0.47 [0.15						
McMullen 2016	-0.17	1.71	0.6%	0.84 [0.03,						
Miller 2015	-1.02	0.4	11.3%	0.36 [0.16	-					
Nagajara 2015	-0.25	1.46	0.9%	0.78 [0.04,	13.62]		<u> </u>			
Napolitano 2015	-0.62		0.8%	0.54 [0.03,						
Peques 2017	-0.29	0.28	23.2%	0.75 [0.43						
Sampathkumar 2016	-0.94	0.35	14.8%	0.39 [0.20						
Vianna 2016	-0.52	1.8	0.6%	0.59 [0.02,						
Total (95% CI)			100.0%	0.64 [0.49	, 0.84]			•		
Heterogeneity: Tau ² = (0.00; Chi ² = 7.98, d	f= 10 (P = 0.63	; I ² = 0%		-				
Test for overall effect: 2	z = 3.29 (P = 0.001)))			(0.01	0.1	1	10	100
							Favours U	v system Favours	s non-UV system	
В			-	tisk Ratio				isk Ratio		
				andom, 95% Cl			IV, Ra	ndom, 95% Cl		
Anderson 2017	-0.89 0.22			.41 [0.27, 0.63]			-	-		
Haas 2014	-0.2 1.58			82 [0.04, 18.12]				*		
Napolitano 2015	-0.13 1.46	S		88 (0.05, 15.36)		-			_	
Vianna 2016	-0.69 2.97	0.5	5% 0.5	0 [0.00, 169.20]	•					
Total (95% CI)		100.	0% 0	.42 [0.28, 0.65]			-	.		
Heterogeneity: Tau ² = 0.1	00 Chil-0 45 df-				<u> </u>					
Test for overall effect: Z =		5 (r = 1	0.00), 1 =		0.01		0.1	1 10	100	
restion orerail effect. 2.	- 4.00 (1 ~ 0.0001)				0.01	-				
						Favo	urs UV system	Favours non-UV	system	

Marra AR, et al. ICHE 2018;39:20-31

EFFECTIVENESS OF TARGETED ROOM DISINFECTION ON HOSPITAL-WIDE ACQUISITION AND INFECTION WITH TARGET PATHOGENS: A SECONDARY ANALYSIS OF THE BETR STUDY

- Goal: To assess the effectiveness of enhanced terminal disinfection on hospital-wide, hospital-acquired incidence of all target organisms
- Methods:
 - Pathogens of interest: MRSA, VRE, C. difficile, MDR-Acinetobacter (target organisms)
 - Outcome: Incidence of target organisms (patients with HAI due to target organism per 10,000 patient days)
- Findings
 - Enhanced terminal room disinfection with UV in a targeted subset of high-risk rooms led to a decrease in hospitalwide incidence of *C. difficile* and VRE. Enhanced disinfection overcomes limitations of standard disinfection strategies and is a potential strategy to reduce the risk of acquisition of multidrug-resistant organisms and *C. difficile*

Anderson SJ, Moehring RW, Weber DJ, et al. Lancet Infect Dis2018;389:845-53

	All patients in catego	ries 1 and 2	Did not enter a seed room (category 1) Entered a seed room (category 2)
Clostridium difficile				
Non-UV disinfection strategy groups	729/779049; 9.36	RR .89	695/757 193; 9·18	34/21856; 15.6
UV disinfection strategy groups	592/739048; 8·01	P=0.031	583/730619; 7.98	9/8429; 10-7
Individual disinfection strategy groups			-	
Reference	372/369737; 10·1		353/358875; 9.84	19/10 862; 17.5
UV	303/370199; 8.18		296/365100; 8.11	7/5099; 13·7
Bleach	357/409 312; 8.72		342/398318; 8.59	15/10994; 13.6
Bleach and UV	289/368849; 7.83		287/365 519; 7.85	2/3330; 6.01
Meticillin-resistant Staphylococcus aureus				
Non-UV disinfection strategy groups	434/753 385; 5.76		365/690566; 5.29	69/62819;11.0
UV disinfection strategy groups	394/716204; 5.50		360/687624; 5·24	34/28580; 11.9
Individual disinfection strategy groups				
Reference	204/357479; 5.71		171/327 342; 5.22	33/30137;11.0
UV	208/358995; 5.79		191/344721; 5·54	17/14 274; 11.9
Bleach	230/395 906; 5.81		194/363224; 5·34	36/32682;11.0
Bleach and UV	186/357209; 5·21		169/342903; 4.93	17/14 306; 11.9
Vancomycin-resistant enterococci		_		
Non-UV disinfection strategy groups	304/777 649; 3.91		235/750260; 3.13	69/27389; 25.2
UV disinfection strategy groups	208/739 366; 2.81	RR .5	6 188/728617; 2·58	20/10749; 18.6
Individual disinfection strategy groups		P=0.0	48	
Reference	119/370 344; 3·21		96/358867; 2.68	23/11 477; 20.0
UV	89/371767; 2.39		79/367108; 2.15	10/4659; 21.5
Bleach	185/407 305; 4·54		139/391393; 3.55	46/15 912; 28.9
Bleach and UV	119/367 599; 3·24		109/361509; 3.02	10/6090; 16-4

Data are number of patients per number of patient days; incidence per 10 000 patient days. UV=ultraviolet light. Bleach=bleach-containing disinfectant (10% hypochlorite).

Table 3: Post-hoc analysis of patients who did not enter a room disinfected with UV

"NO TOUCH" ROOM DECONTAMINATION: ADVANTAGES AND DISADVANTAGES OF UV DEVICES AND HP SYSTEMS

Advantages

- Reliable biocidal activity against a wide range of pathogens (UV, HP)
- Surfaces and equipment decontaminated (UV, HP)
- Demonstrated effectiveness to reduce HAIs in before-after studies (UV, HP) and randomized clinical trial (UV)
- Residual free and does not give rise to health and safety concerns (UV, HP)


Differences and disadvantages

- Can only be done for terminal disinfection (UV, HP)
- All patients and staff must be removed from room (UV, HP)
- Time: UV=5-15 min (vegetative bacteria), 10-45 min (*C. difficile*); HP=1.5-2.5 hr
- UV requires direct or indirect line of sights unlike HP
- HP requires the HVAC system be sealed off unlike UV
- Substantial capital equipment costs (UV, HP)
- Does not remove dust and stains which are important to patients/visitors (UV, HP)

Weber DJ and Rutala WA. (unpublished)

VALUE OF SEQUENTIAL INTERVENTIONS TO IMPROVE DISINFECTION OF *C. difficile* ROOMS

- Design: Prospective intervention
- Interventions
 - 1. Fluorescent markers used to provide monitoring and feedback on cleaning
 - 2. UV irradiation used for terminal disinfection of CDI rooms
 - 3. Enhanced disinfection of CDI rooms including dedicated daily disinfection team
- Results
 - Cleaning improvement: $47\% \rightarrow 87\%$
 - Reduction CDI positive cultures: 67% (baseline)→57% (1) →35% (2)→7% (3)



EFFECTIVENESS OF COPPER-COATED SURFACES IN REDUCING ENVIRONMENTAL CONTAMINATION

Goal: To assess ability of CU to reduce surface colonization Design: Interventional, comparative crossover trial Methods:

- Copper coated surfaces: beds (i.e., with coated upper, lower, and side rails) and accessories (i.e., coated side table, IV pole stands, side-cart handles)
- Phase 2a: coated items were placed next to non-coated ones (controls) in both compartments A and B; during Phase 2b, all copper-coated items were placed in compartment A, and all non-coated ones (controls) in compartment B.

Results:

- Copper coating reduced percent of contaminated surfaces, percent of MDRO contamination (GNR, enterococci), total bioburden, and GNR bioburden
- Reductions more pronounced in Phase 2b

	Copper-Coated Surfaces $(n = 311)$	Standard (Noncopper) Surfaces (n = 374)	P Value ^b
0: 1 Pl - 2	(1-511)	(1-5/4)	1 value
Study Phase 2			
Colonized surfaces, no. (%)	173 (55.6)	271 (72.5)	<.0001
Surfaces with Gram-negative bacteria, no. (%)	43 (13.8)	85 (22.7)	.003
Surfaces with <i>Enterococcus</i> spp., no. (%)	4 (1.3)	17 (4.5)	.014
Surfaces with A. baumannii, no. (%)	28 (9)	51 (13.6)	.07
Surfaces with K. pneumoniae, no. (%)	1 (0.3)	5 (1.3)	.156
Surfaces with S. aureus, no. (%)	2 (0.6)	1 (0.3)	.466
Bacterial colonies, mean cfu/100 cm ² (\pm SD)	2,858 (±8,662)	7,631 (±30,642)	.008
Colonies of Gram-negative bacteria, mean $cfu/100 cm^2 (\pm SD)$	$261 (\pm 1,380)$	1,266 (±8,893)	.049
Study Phase 2a			
	Copper-Coated Surfaces	Standard (Noncopper) Surfaces	P Value ^b
	(n = 130)	(n = 217)	
Colonized surfaces, no. (%)	93 (71.5)	166 (76.5)	.311
Surfaces with Gram-negative bacteria, no. (%)	19 (14.6)	51 (23.5)	.053
Surfaces with Enterococcus spp., no. (%)	1 (0.8)	5 (2.3)	.417
Surfaces with A. baumannii, no. (%)	12 (9.2)	27 (12.4)	.386
Surfaces with K. pneumoniae, no. (%)	0	2 (0.9)	.272
Surfaces with S. aureus, no. (%)	0	0	
Bacterial colonies, mean $cfu/100 cm^2 (\pm SD)$	3,225 (±8,961)	$5,425(\pm 15,016)$.131
Colonies of Gram-negative bacteria, mean $cfu/100 cm^2 (\pm SD)$	$257(\pm 1,315)$	$1,159(\pm 8,619)$.237
Study Phase 2b		1,107 (10,017)	
	Copper-Coated Surfaces	Standard (Noncopper) Surfaces	P Value ^b
	(n = 181)	(n = 157)	
Colonized surfaces, no. (%)	80 (44.2)	105 (66.4)	<.001
Surfaces with Gram-negative bacteria, no. (%)	24 (13.3)	34 (21.7)	.044
Surfaces with <i>Enterococcus</i> spp., no. (%)	3 (1.7)	12 (7.6)	.014
Surfaces with <i>A. baumannii</i> , no. (%)	16 (8.8)	24 (15.3)	.091
Surfaces with <i>K. pneumoniae</i> , no. (%)	1 (0.6)	3 (1.9)	.249
Surfaces with <i>S. aureus</i> , no. (%)	2(1.1)	1 (0.95)	.186
Bacterial colonies, mean cfu/100 cm ² (\pm SD)	$2,594(\pm 8,455)$	$10,680 (\pm 43,780)$.015
Colonies of Gram-negative bacteria, mean $(\pm 3D)$	$263 (\pm 1,427)$	$1,414 (\pm 9,283)$.101
(± 5D)	203 (11,427)	1,114 (1),200)	.101

Souli M, et al. ICHE 2017;38:765-771

FUTURE RESEARCH NEEDS: ROOM DISINFECTION USING UV, DEMONSTRATING EFFECTIVENESS

• IDSA Guideline on *C. difficile* ():

- "There are limited data at this time to recommend use of automated, terminal disinfection using a sporicidal method for CDI prevention (no recommendation)"
- Study limitations: "before–after study designs, inappropriate statistical methods to analyze the data, other concurrent interventions, high baseline incidence of CDI prior to implementation, reduction of CDI back to baseline prior to no-touch technology implementation, and reductions driven by results from single units without apparent impact on other units"
- Issues to be addressed in a future RCT to demonstrate effectiveness of UV for room disinfection
 - Need to use the hospital (best choice) or at least hospital unit (i.e., ICU) as the unit for randomization/analysis
 - Need to control for frequency of hand hygiene, chemical disinfection, other interventions
 - Ideally, assess for colonization not just infection; ideally use molecular methods to demonstrate transmission
 - Result of design: Best design = Cluster randomized study : High cost (\$millions), need for informed consent, prolonged study time
- Cost effective analysis demonstrating benefit of UV room disinfection

FUTURE RESEARCH NEEDS: UV DEVICES FOR SURFACE DISINFECTION

- Room disinfection devices
 - Demonstrate overall hospital reduction in HAIs by using UV devices for patients on contact precautions (e.g., CRE)
 - Assess effectiveness of room disinfection units when used for terminal disinfection of all patients (not just those on contact isolation)
 - Assess effectiveness in other hospital settings: Operating room, play rooms, common areas, ambulances, etc.
 - Assess effectiveness in other settings: Nursing homes, day care centers, veterinary hospitals, etc.
- Other potential uses of UV (demonstrating effectiveness: 1) kills inoculated surfaces; 2) kills microbes on actual hospital surfaces; 3) reduces HAIs in hospital unit (ideally a RCT); 4) reduces overall hospital HAIs
 - Assess effectiveness for disinfecting shared medical equipment, personal devices (e.g., stethoscopes, computers, cell phones, etc.)
 - Assess effectiveness for use of handheld UV devices
 - Assess effectiveness for use of barriers allowing UV devices to be used in multi-bed rooms
- UV for disinfection of other sources/reservoirs for HAIs: Water (sink traps, facets), air (OR), food

OTHER IMPORTANT SURFACES: UV MAY HAVE A ROLE IN DISINFECTION



Curtains frequently contaminated with MDROs. Possible solutions: disposable curtains, antimicrobial curtains, routine disinfection of grab area. Rutala WA, et al. ICHE 2014;42:426



Floors contaminated with MDROs. May serve as source for contaminating socks and shoes leading to dissemination. Possible solutions: EVS education, use disinfectant on floors. Donskey C. AJIC 2019;47S:A90



Shared patient items may transmit MDROs. Possible solution: Assess cleaning (fluorescent dye, ATP) with feedback. Donskey C. AJIC 2019;47S:A90



Fabric covered chairs may be contaminated with MDROs leading to transmission among patients. Possible solution: Use only non-porous furniture in hospital to facilitate cleaning & disinfection. Noskins GA, et al. AJIC 2000;28:311.

TECHNOLOGIES TO IMPROVE DISINFECTION OF ENVIRONMENTAL SURFACES: COMPETITION FOR UV DEVICES

• Terminal disinfection: "No touch" systems and devices

- UV light devices: UV-C or pulsed xenon
- Hydrogen peroxide systems: Vapor or aerosol
- Portable devices: UV, steam, chemical disinfectant (e.g., hydrogen peroxide, hypochlorite)
- Daily and terminal disinfection: New surface disinfectants
 - Surface disinfectants with persistence*
 - Improved hydrogen peroxide*
 - Electrochemically activated saline solution
- Continuous disinfection: "self disinfecting" surfaces or room disinfection systems
 - Heavy metal surface coatings: Silver, copper
 - Germicide impregnated surfaces (e.g., light activated germicides)
 - Low dose continuous hydrogen peroxide systems
 - "Blue" lights (i.e., visible lights near UV spectrum)

* Already commercially available

THANK YOU!!

